On the other hand, a study has been published presenting that decreased mRNA levels of SMAD2, SMAD3, and SMAD4 are frequent events, respectively in 71.4%, 78.6%, and 78.6% of analyzed endometrial cancer samples. The gene discussed is SMAD2; the disease is endometrial cancer.